IMRX Stock Analysis: Immuneering | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 336m USD | 12M Return: 25.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.28M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Immuneering Corporation (NASDAQ: IMRX) is a late-stage oncology biotech developing cancer therapies intended for broad patient populations, with its lead candidate IMM-1-104 (atebimetinib), a dual-MEK inhibitor, currently in a Phase 3 trial for pancreatic and non-small cell lung cancers driven by RAS or RAF mutations. Its second program, IMM-6-415 (envometinib), is in Phase 1/2a for solid tumors, supported by additional early-stage deep cyclic inhibitor discovery work. The company has clinical supply agreements with Regeneron (combining atebimetinib with Libtayo in RAS-mutant NSCLC) and Eli Lilly (combining it with olomorasib in KRAS G12C-mutant NSCLC), which provide combination-drug access without disclosing co-development economics.
Founded in 2008 and headquartered in Cambridge, Massachusetts, Immuneering went public in July 2021 and is classified as a micro-cap biotechnology company within the Health Care sector. As a clinical-stage developer with no currently approved products, its business model centers on advancing a pipeline of small-molecule candidates, funded through capital markets and partnerships, until regulatory approval and commercialization can generate recurring product revenue.
- Phase 3 atebimetinib data readout in pancreatic cancer
- Atebimetinib combination trials advance with Regeneron and Lilly
- Cash burn raises dilution risk for micro-cap biotech
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 105.8 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.00 > 3% & CFO -49.7m > Net Income -54.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 32.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.0m) vs 12m ago 23.87% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.43%; Δ -1.43% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.73 (Total Current Assets 161b - Total Current Liabilities 4.97b) / Total Assets 215b |
| B: -1.37 (Retained Earnings -294b / Total Assets 215b) |
| C: -0.00 (EBIT TTM -59.6m / Avg Total Assets 107b) |
| D: 24.91 (Book Value of Equity 207b / Total Liabilities 8.29b) |
| Altman-Z'' = 26.47 = AAA |
As of July 08, 2026, the stock is trading at USD 5.10 with a total of 1,000,419 shares traded. Over the past week, the price has changed by +0.99%, over one month by +29.77%, over three months by -2.49% and over the past year by +25.93%.
Current recommended Stop Loss: 4.70 (which is 7.8% or 1.2 ATR below the current price).
Immuneering has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy IMRX.
- StrongBuy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17 | 233.3% |
P/S = 374386.8864
P/B = 1.629
Revenue TTM = 0.0 USD
EBIT TTM = -59.6m USD
EBITDA TTM = -58.9m USD
Long Term Debt = 3.32b USD (estimated: total debt 3.73b - short term 413.2m)
Short Term Debt = 413.2m USD (from shortTermDebt, last quarter)
Debt = 3.73b USD (from shortLongTermDebtTotal, last quarter) + Leases 3.73m
Net Debt = 3.58b USD (calculated: Debt 3.73b - CCE 156.7m)
Enterprise Value = 3.91b USD (335.8m + Debt 3.73b - CCE 156.7m)
Interest Coverage Ratio = unknown (Ebit TTM -59.6m / Interest Expense TTM 0.0)
EV/FCF = -78.40x (Enterprise Value 3.91b / FCF TTM -49.9m)
FCF Yield = -1.28% (FCF TTM -49.9m / Enterprise Value 3.91b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 971k) / Revenue TTM)
Tobins Q-Ratio = 0.02 (Enterprise Value 3.91b / Total Assets 215b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.73b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -47.1m (EBIT -59.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 32.45 (Total Current Assets 161b / Total Current Liabilities 4.97b)
Debt / Equity = 0.02 (Debt 3.73b / totalStockholderEquity, last quarter 207b)
Debt / EBITDA = -60.78 (negative EBITDA) (Net Debt 3.58b / EBITDA -58.9m)
Debt / FCF = -71.67 (negative FCF - burning cash) (Net Debt 3.58b / FCF TTM -49.9m)
Total Stockholder Equity = 51.7b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.05% (Net Income -54.4m / Total Assets 215b)
RoE = -0.11% (Net Income TTM -54.4m / Total Stockholder Equity 51.7b)
RoCE = -0.11% (EBIT -59.6m / Capital Employed (Equity 51.7b + L.T.Debt 3.32b))
RoIC = -0.02% (negative operating profit) (NOPAT -47.1m / Invested Capital 210b)
WACC = 1.16% (E(335.8m)/V(4.07b) * Re(14.08%) + D(3.73b)/V(4.07b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.08% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 98.88 | Cagr: 19.88%
[DCF] Fair Price = unknown (Cash Flow -49.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.57 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.27 | Chg30d=+3.77% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.32 | Chg30d=+3.96% | Revisions=-17% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.14 | Chg30d=+4.21% | Revisions=+38% | GrowthEPS=+10.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.34 | Chg30d=+1.11% | Revisions=+29% | GrowthEPS=-17.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +21% (up=10, down=6)